| Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer L Derosa, B Routy, AM Thomas, V Iebba, G Zalcman, S Friard, J Mazieres, ... Nature medicine 28 (2), 315-324, 2022 | 264 | 2022 |
| Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real … A Desilets, F Blanc-Durand, S Lau, T Hakozaki, R Kitadai, J Malo, ... European Journal of Cancer 142, 83-91, 2021 | 60 | 2021 |
| Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI) A De Giglio, L Mezquita, E Auclin, F Blanc-Durand, M Riudavets, ... Cancers 12 (10), 2827, 2020 | 43 | 2020 |
| Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer A Leary, C Genestie, F Blanc-Durand, S Gouy, A Dunant, A Maulard, ... Cancer Immunology, Immunotherapy 70, 519-531, 2021 | 36 | 2021 |
| Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis A Auguste, F Blanc-Durand, M Deloger, A Le Formal, R Bareja, DC Wilkes, ... Cells 9 (6), 1496, 2020 | 29 | 2020 |
| Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics L Mezquita, I Preeshagul, E Auclin, D Saravia, L Hendriks, H Rizvi, ... European Journal of Cancer 151, 211-220, 2021 | 28 | 2021 |
| Tepotinib Efficacy in a Patient with Non‐Small Cell Lung Cancer with Brain Metastasis Harboring an HLA‐DRB1‐MET Gene Fusion F Blanc‐Durand, R Alameddine, AJ Iafrate, D Tran‐Thanh, YC Lo, N Blais, ... The Oncologist 25 (11), 916-920, 2020 | 25 | 2020 |
| Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study A Bayle, L Belcaid, M Aldea, D Vasseur, F Peyraud, C Nicotra, A Geraud, ... Annals of Oncology 34 (4), 389-396, 2023 | 24 | 2023 |
| Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. F Blanc-Durand, C Genestie, EY Galende, S Gouy, P Morice, P Pautier, ... Gynecologic Oncology 160 (1), 279-284, 2021 | 21 | 2021 |
| Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer A Clément‐Zhao, M Auvray, H Aboudagga, F Blanc‐Durand, ... BJU international 121 (2), 203-208, 2018 | 20 | 2018 |
| Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated A De Giglio, L Mezquita, E Auclin, F Blanc-Durand, L El-Amarti, ... Annals of Oncology 30, xi16, 2019 | 16 | 2019 |
| Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. F Blanc-Durand, E Yaniz, C Genestie, E Rouleau, D Berton, A Lortholary, ... Journal of Clinical Oncology 39 (15_suppl), 5513-5513, 2021 | 15 | 2021 |
| Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a … A Bayle, F Peyraud, L Belcaid, M Brunet, M Aldea, R Clodion, P Dubos, ... Annals of Oncology 33 (12), 1328-1331, 2022 | 12 | 2022 |
| Next-generation sequencing on circulating tumor DNA in advanced solid cancer: swiss army knife for the molecular tumor board? A review of the literature focused on FDA approved … D Vasseur, H Sassi, A Bayle, M Tagliamento, B Besse, C Marzac, A Arbab, ... Cells 11 (12), 1901, 2022 | 12 | 2022 |
| Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated … F Blanc-Durand, E Auclin, D Planchard, SP Aix, L Hendriks, IG Sullivan, ... Annals of Oncology 30, xi5, 2019 | 12 | 2019 |
| Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer E Auclin, J Benitez-Montanez, M Tagliamento, F Parisi, T Gorria, ... Lung Cancer 178, 116-122, 2023 | 10 | 2023 |
| Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience V Marmouset, J Decroocq, S Garciaz, G Etienne, A Belhabri, S Bertoli, ... Clinical Cancer Research 28 (23), 5211-5220, 2022 | 10 | 2022 |
| Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision … A Bayle, F Peyraud, L Belcaid, M Brunet, M Aldea, R Clodion, P Dubos, ... Annals of Oncology: Official Journal of the European Society for Medical …, 2022 | 10 | 2022 |
| Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours C Genestie, F Blanc-Durand, A Auguste, P Pautier, A Dunant, JY Scoazec, ... British Journal of Cancer 122 (4), 564-568, 2020 | 10 | 2020 |
| A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer F Blanc-Durand, E Yaniz-Galende, A Llop-Guevara, C Genestie, V Serra, ... Gynecologic Oncology 171, 106-113, 2023 | 9 | 2023 |
